Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.

Afficher d'autres versions (1)

BACKGROUND: Tumour necrosis factor (TNF)-alpha inhibitors are beneficial for the treatment of rheumatoid arthritis (RA) in terms of reducing the risk of joint damage, improving physical function and improving quality of life. This Cochrane review is an update of a review of the treatment of RA with...

Description complète

Détails bibliographiques
Auteurs principaux:	Ruiz Garcia, V, Jobanputra, P, Burls, A, Cabello, J, Vela Casasempere, P, Bort-Marti, S, Kynaston-Pearson, F
Format:	Journal article
Langue:	English
Publié:	2014

Documents similaires

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
par: Ruiz Garcia, V, et autres
Publié: (2011)

Certolizumab pegol in therapy for rheumatoid arthritis
par: Galina Viktorovna Lukina, et autres
Publié: (2012-06-01)

Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis
par: M Connock, et autres
Publié: (2010-10-01)

QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL
par: Vera Nikolayevna Amirdjanova, et autres
Publié: (2012-10-01)

New aspects of the pharmacotherapy of rheumatoid arthritis: a focus on certolizumab pegol
par: Evgeniy L'vovich Nasonov, et autres
Publié: (2011-02-01)

Multifocal tuberculosis on certolizumab pegol in a patient followed for rheumatoid arthritis
par: Emna Hannech, et autres
Publié: (2021-06-01)

New treatment possibilities for rheumatoid arthritis: the Russian experience in using certolizumab pegol
par: Dmitry Evgenyevich Karateev, et autres
Publié: (2012-04-01)

EFFICACY OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF PSORIATIC ARTHRITIS
par: T. V. Korotaeva, et autres
Publié: (2015-10-01)

Certolizumab pegol – new option in the treatment of psoriatic arthritis
par: Maria Majdan, et autres
Publié: (2014-07-01)

Certolizumab pegol in the treatment of spondyloarthritis
par: Mariusz Korkosz
Publié: (2014-09-01)

Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis
par: Smolen, JS, et autres
Publié: (2024)

COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL PLUS METHOTREXATE OR AS MONOTHERAPY FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS IN THE UNITED KINGDOM
par: Purcaru, O, et autres
Publié: (2010)

Prefilled certolizumab pegol (Cimzia&reg;) syringes for self-use in the treatment of rheumatoid arthritis
par: J Rosa, et autres
Publié: (2010-08-01)

CERTOLIZUMAB PEGOL IN THE TREATMENT OF AXIAL SPONDYLOARTHRITIS
par: Sh. F. Erdes
Publié: (2016-02-01)

Eosinophilic Annular Erythema Due to Certolizumab Pegol Therapy for Rheumatoid Arthritis Post-COVID-19 Vaccine
par: Andrea Bassi, et autres
Publié: (2023-04-01)

The efficacy of certolizumab pegol in rheumatoid arthritis assessed by gray scale and power Doppler ultrasonography: case reports
par: José Alexandre Mendonça, et autres
Publié: (2019-02-01)

Exposure–Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis
par: Stéphane Paul, et autres
Publié: (2020-07-01)

Drug Induced Thrombotic Microangiopathy with Certolizumab Pegol
par: Mehmet Baysal, et autres
Publié: (2018-09-01)

Treatment of pyoderma gangrenosum in pregnancy with certolizumab pegol
par: Lindsey J. Wanberg, et autres
Publié: (2024-06-01)

Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post-hoc analysis of clinical trials
par: Tanaka, Y, et autres
Publié: (2023)

Experience with long-term use of certolizumab pegol (Cimzia)
par: Karine Arnoldovna Lytkina, et autres
Publié: (2013-10-01)

Experience with long-term use of certolizumab pegol (Cimzia)
par: Karine Arnoldovna Lytkina, et autres
Publié: (2013-10-01)

A genome-wide screen for variants influencing certolizumab pegol response in a moderate to severe rheumatoid arthritis population.
par: Ian R White, et autres
Publié: (2022-01-01)

A genome-wide screen for variants influencing certolizumab pegol response in a moderate to severe rheumatoid arthritis population
par: Ian R. White, et autres
Publié: (2022-01-01)

Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data
par: Vivian P. Bykerk, et autres
Publié: (2023-02-01)

Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study
par: Glatt, S, et autres
Publié: (2019)

Quantitation of certolizumab pegol by validated liquid chromatography methods
par: Clóvis Dervil Appratto Cardoso Júnior, et autres
Publié: (2023-11-01)

Certolizumab pegol in treatment of Crohn's disease with perianal lesions
par: I.L. Khalif, et autres
Publié: (2018-04-01)

Active axial spondyloarthritis: potential role of certolizumab pegol
par: Ranatunga S, et autres
Publié: (2014-02-01)

Certolizumab pegol w leczeniu reumatoidalnego zapalenia stawów
par: Piotr Wiland, et autres
Publié: (2011-08-01)

An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy
par: Acosta-Felquer ML, et autres
Publié: (2016-03-01)

CERTOLIZUMAB PEGOL IN THE TREATMENT OF TAKAYASU ARTERITIS: THE FIRST EXPERIENCE AND PROSPECTS
par: P. I. Novikov, et autres
Publié: (2018-07-01)

Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol.
par: Hazes, J, et autres
Publié: (2010)

Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis
par: A. Spadaro, et autres
Publié: (2013-07-01)

Patient Adherence and Efficacy of Certolizumab Pegol in the Management of Crohn's Disease
par: Wojciech Blonski, et autres
Publié: (2012-04-01)

Efficacy and tolerability of certolizumab pegol in Crohn's disease in clinical practice
par: O V Knyazev, et autres
Publié: (2018-06-01)

Certolizumab pegol – Tumor necrosis factor inhibitor for refractory uveitis
par: Yael Sharon, et autres
Publié: (2020-06-01)

Possible relationship between certolizumab pegol and arrhythmias: report of two cases
par: R. Talotta, et autres
Publié: (2016-09-01)

Effectiveness of Certolizumab Pegol in Treating Rheumatoid Arthritis Patients with Persistent Inflamed Residual Mono- or Oligosynovitis Resistant to Prior TNF-α Inhibitors
par: Syuichi Koarada, et autres
Publié: (2015-01-01)

Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment
par: Jeffrey R. Curtis, et autres
Publié: (2017-12-01)